Ozempic’s hidden pregnancy risk few women know about

Published recently in the esteemed Medical Journal of Australia, the groundbreaking study meticulously analysed an extensive dataset comprising over 1.6 million women aged 18 to 49 who attended general practices across Australia between the years 2011 and 2022. Of the 18,010 women identified as receiving their initial prescription for GLP-1 receptor agonists within this period, a concerning statistic emerged: merely 21% had a documented record of using any form of contraception at the time of prescription. This finding underscores a critical oversight in reproductive health counselling within primary care settings, particularly given the rapid uptake of these powerful pharmacological agents.

The Ascent of GLP-1 Receptor Agonists: A Medical Revolution with Unforeseen Challenges

Originally engineered and approved for the management of type 2 diabetes, GLP-1 receptor agonists have undergone a remarkable evolution in their clinical application. Their profound effects on appetite suppression, delayed gastric emptying, and subsequent weight loss have propelled them into the forefront of obesity management strategies globally. This shift in utility has been dramatic, with the Flinders University study explicitly noting that the predominant proportion of current GLP-1 prescriptions are now being issued to women without a pre-existing diagnosis of diabetes. This expansion into the weight-loss market has been fuelled by a growing recognition of obesity as a chronic disease requiring multifaceted interventions, alongside the impressive efficacy demonstrated by these drugs in clinical trials.

Associate Professor Luke Grzeskowiak, a lead author of the study and a distinguished pharmacist from the College of Medicine and Public Health at Flinders University, articulated the scale of this phenomenon. "We’re seeing widespread use of these medications among women of childbearing age, but very little evidence that contraception is being considered as part of routine care," he stated, highlighting the urgency of the issue. He further elaborated, "In 2022 alone, more than 6,000 women initiated treatment with GLP-1s, and strikingly, over 90% of these individuals did not have a diabetes diagnosis." This data points to a burgeoning public health concern, as the drugs, while "incredibly helpful" for many, are "not risk-free, especially during pregnancy."

Understanding GLP-1 Receptor Agonists: Mechanism, History, and Popularity

GLP-1 receptor agonists mimic the action of glucagon-like peptide-1, a natural hormone that plays a crucial role in glucose metabolism and appetite regulation. By activating GLP-1 receptors, these medications enhance insulin secretion in a glucose-dependent manner, suppress glucagon release, slow gastric emptying, and promote satiety in the brain. The first GLP-1 agonist, exenatide, was approved for type 2 diabetes in 2005. Subsequent innovations led to the development of longer-acting analogues like liraglutide, semaglutide (marketed as Ozempic for diabetes and Wegovy for weight loss), and tirzepatide (marketed as Mounjaro for diabetes and Zepbound for weight loss), which also acts on GIP receptors. Their journey from diabetes management to a blockbuster solution for obesity has been swift, driven by compelling efficacy data showing average weight loss ranging from 15% to over 20% of body weight, far surpassing previous pharmacological options. This high demand has, at times, led to supply shortages, further underscoring their popularity and the broad demographic now seeking these treatments.

The appeal of these drugs is undeniable in a society grappling with rising rates of overweight and obesity. According to the Australian Institute of Health and Welfare, approximately two-thirds of Australian adults are overweight or obese, contributing to a significant burden of chronic diseases. For many, GLP-1s offer a medical pathway to achieving substantial weight loss where diet and exercise alone have proven insufficient, thus improving metabolic health and quality of life. However, this therapeutic promise must be balanced with a rigorous understanding of potential side effects and contraindications, particularly for vulnerable populations like pregnant women.

Detailed Study Findings: Pregnancy Rates and Fertility Insights

The Flinders University study’s findings extend beyond the mere absence of contraception. It meticulously tracked pregnancy outcomes among the cohort, revealing that 2.2% of women became pregnant within six months of commencing GLP-1 treatment. This figure, while seemingly low, translates to hundreds of potential exposures given the large number of women initiating these medications. Critically, the study identified specific demographic patterns associated with higher pregnancy rates. Younger women diagnosed with diabetes exhibited the highest rates of conception, a demographic often at a higher risk for unintended pregnancies generally. Furthermore, women without a diabetes diagnosis in their early thirties also demonstrated elevated pregnancy rates, suggesting that the primary indication for the drug (weight loss) might be a contributing factor.

One particularly intriguing and clinically significant finding was the observation that women diagnosed with polycystic ovary syndrome (PCOS) were twice as likely to conceive while on GLP-1 therapy. PCOS is a common endocrine disorder characterised by hormonal imbalances, irregular periods, and often, insulin resistance and obesity, which can contribute to infertility. The weight loss achieved through GLP-1 agonists appears to improve the metabolic profile and hormonal balance in these women, thereby inadvertently enhancing fertility. While an improvement in fertility can be a desired outcome for some women with PCOS, when it occurs unexpectedly during GLP-1 treatment, it amplifies the risk of an unplanned and potentially unsafe pregnancy given the medication’s known risks. This finding underscores the dual-edged sword of GLP-1s, where a beneficial side effect in one context becomes a cautionary tale in another, especially in the absence of robust contraceptive planning. The study unequivocally demonstrated that women who were using contraception at the time of prescribing had a significantly lower risk of pregnancy, reinforcing the paramount importance of such preventative measures.

The Science of Concern: Potential Risks to Fetal Development

The concerns surrounding GLP-1 exposure during pregnancy are not merely theoretical. While comprehensive human data are still limited due to ethical considerations in conducting trials on pregnant women, existing evidence, primarily from animal studies, provides a robust basis for caution. A previous systematic review of animal studies conducted by the University of Amsterdam, for instance, established a clear link between GLP-1 exposure during pregnancy and adverse fetal outcomes. These included reduced fetal growth, significant skeletal abnormalities, and other developmental anomalies. The precise mechanisms of harm are still under investigation but are thought to relate to the drug’s effects on nutrient absorption, glucose metabolism, and direct receptor interactions within developing fetal tissues.

Given the biological plausibility of these findings and the conserved nature of many physiological pathways between mammalian species, regulatory bodies and clinicians adopt a precautionary principle. The potential for teratogenicity (causing birth defects) or other adverse developmental effects in humans remains a serious concern, necessitating a conservative approach to prescribing for women who could become pregnant.

Regulatory Landscape and Clinical Practice Gaps

International and national regulatory bodies have issued clear guidance regarding GLP-1 receptor agonists and pregnancy. The UK’s National Institute for Health and Care Excellence (NICE), for example, explicitly advises that women using GLP-1 receptor agonists should avoid pregnancy and utilise effective contraception. Similar warnings are embedded in product information leaflets and prescribing guidelines issued by bodies such as the Therapeutic Goods Administration (TGA) in Australia and the Food and Drug Administration (FDA) in the United States. These guidelines generally recommend discontinuing GLP-1 agonists at least two months prior to planned conception due to their pharmacokinetic profiles (how the drug moves through the body) and potential for residual effects.

Despite these unequivocal recommendations, the Flinders University study highlights a significant disconnect between official guidance and real-world clinical practice in Australia. "Whilst the UK advises that women using GLP-1 receptor agonists should avoid pregnancy and use effective contraception, this advice is not being followed consistently in Australian clinical practice," observed Associate Professor Grzeskowiak. This inconsistency could stem from several factors, including time constraints during routine consultations, insufficient awareness among some prescribers regarding the specific reproductive risks of these newer drugs, or a lack of standardised protocols for reproductive health screening and counselling when initiating GLP-1 therapy.

Broader Implications and Calls to Action

The findings of this study carry profound implications for public health, medical ethics, and future clinical practice. On a public health level, the widespread, unchecked use of GLP-1s without adequate contraception could lead to an increase in unintended pregnancies exposed to potentially harmful substances, resulting in a higher incidence of adverse pregnancy outcomes. This, in turn, could place additional strain on healthcare resources, emotionally burden families, and potentially lead to legal and ethical dilemmas for patients and providers.

Ethically, the principle of informed consent is paramount. Patients must be fully apprised of all potential risks and benefits of a medication, particularly when those risks pertain to future pregnancies. The study suggests that many women are not receiving comprehensive counselling on reproductive risks and contraceptive needs when prescribed GLP-1s. This raises questions about the adequacy of current prescribing practices and the need for enhanced training and awareness among healthcare professionals.

Associate Professor Grzeskowiak issued a clear call to action: "We need to ensure that reproductive health is part of every conversation when these drugs are prescribed to any women of childbearing age." This proactive approach would involve a mandatory discussion about pregnancy risk, the importance of effective contraception, and the implications of unintended conception during therapy. He further emphasised, "It is also vitally important that we have clearer practice recommendations and guidelines for those prescribing GLP-1s to women to ensure their safe and effective use." Such guidelines could include mandatory checklists for prescribers, educational materials for patients, and integration with electronic health records to flag potential risks.

Addressing the Gap: Perspectives from Related Parties

While the Flinders University study focuses on data, the implications naturally extend to various stakeholders. General practitioner associations, such as the Royal Australian College of General Practitioners (RACGP), are likely to view these findings as a critical reminder of the complex role GPs play in holistic patient care. They might emphasize the need for ongoing professional development, updated clinical tools, and adequate consultation times to address sensitive topics like reproductive health. The challenge for GPs lies in balancing the significant benefits of GLP-1s for weight management with the need to thoroughly discuss all potential risks, often within a busy clinical schedule.

Women’s health advocacy groups would undoubtedly echo the call for comprehensive reproductive counselling. They typically champion patient autonomy, informed choice, and access to accurate, unbiased information. Their perspective would likely highlight the importance of empowering women to make educated decisions about their health and fertility, ensuring that medical treatments for one condition do not inadvertently jeopardise another aspect of their well-being. Pharmaceutical companies, while providing extensive product information and warnings, may also be prompted to reinforce these messages more prominently in their educational materials for healthcare professionals and consumers.

Future Research and Patient Guidance

The authors of the Flinders University study rightly conclude that further studies evaluating the long-term impact of these medications on human pregnancy and unborn babies are warranted. Such research, while challenging to conduct, is crucial for refining clinical guidelines and providing definitive answers regarding safety. This could involve large-scale observational studies, robust registries of GLP-1 exposed pregnancies, and collaboration with international research efforts to pool data and accelerate understanding.

In the interim, the most vital advice for women considering or currently taking GLP-1 receptor agonists is to engage in open and thorough communication with their healthcare providers. "Our advice is to speak to your GP about the risks and benefits of GLP-1 medicines before taking them, and only take those prescribed by a healthcare professional," Associate Professor Grzeskowiak urged. This dialogue should encompass discussions about future family planning, the need for effective contraception, and the appropriate timing for discontinuing the medication if pregnancy is desired or occurs. Ensuring that reproductive health is an integral part of the prescribing conversation is not merely a recommendation but a fundamental requirement for the safe and ethical use of these powerful new weight-loss tools.

Acknowledgements: The research was made possible through salary support received by Luke Grzeskowiak from a Channel 7 Children’s Research Foundation Fellowship (CRF-210323). Additionally, the contributions of members of the SPHERE Centre of Research Excellence in Women’s Sexual and Reproductive Health in Primary Care (SPHERE 2.0 CRE), funded by the National Health and Medical Research Council (APP2024717), are acknowledged.